B+
Bull case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
DRIO
DarioHealthBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+75.9
Score
AI commentary
Sentiment is mildly constructive but clearly lower-conviction than a typical growth-medtech long. The March 2026 update improved the operating-loss and pipeline narrative, yet the 10-K still reads as a cash-runway and execution story first, not a proven breakout. The April 13, 2026 8-K announcing John R. Palumbo's board appointment is directionally positive for governance/commercial credibility, but it does not by itself change the core thesis [#8-K-2026-04-13].
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15eventNext earnings update must confirm post-Twill revenue stabilizationHigh impact
March 19, 2026 results showed Q4 revenue of $5.2M versus $5.0M in Q3, but management also said the year-over-year decline reflected a large national health plan client from the Twill acquisition that was not renewed at the start of 2025 [#PR-2026-03-19]. The next quarterly release is the first clean checkpoint on whether sequential growth is durable once that legacy drag is lapped.
2026-05-15catalystQ1 2026 filing tests liquidity and covenant headroomHigh impact
The key near-term issue is whether Dario can keep shrinking cash burn without tripping lender constraints. The 10-K said cash and short-term deposits were about $26.0M at December 31, 2025, while the amended Callodine facility requires at least $10.0M of consolidated unencumbered liquid assets and leaves part of remaining availability discretionary [#10-K-2026-03-19]. A clean Q1 update would support runway; a weak filing could quickly revive dilution/default concerns.
2026-12-31catalyst2026 conversion of contracted ARR and pipeline into recognized revenueHigh impact
Management said 2025 produced 85 new contracts, $12.9M of contracted and late-stage ARR expected to contribute in 2026 and 2027, and a commercial pipeline of $122M across roughly 230 mostly B2B2C opportunities, with more than 70% multi-condition [#PR-2026-03-19]. If those wins convert on schedule, the setup supports operating leverage; if conversion slips, the equity likely stays trapped in monitoring mode.
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology